ClinicalTrials.gg
CompletedNCT00791323Updated Sep 23, 2011Results posted

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

A Phase 4 interventional study of Ketorolac 0.4% and Lubricating Eye Drop in Inflammation, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-23.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.

Enrollment
888th of 956
9 · median 45
Started
2008
with 34 others
Phase 4
73 of 1,173
7 open now
Registered
214th of 1,173
by date

Among the 1,173 studies in Inflammation with a site in United States, this one is the 888th largest by enrollment of the 956 interventional ones that give a count, is one of 35 that started in 2008, is one of 73 in phase 4, and was the 214th registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.

Browse Inflammation studies →

Open to participants now

161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,173 studies in Inflammation with a site in United States, or all of them as a file.
02

Study summary

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

03

Conditions studied

  • Inflammation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo phakic IOL implantation

Exclusion criteria

Exclusion Criteria:

  • History of intraocular surgery in the operative eye
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    1

    Ketorolac 0.4%

    Drug: Ketorolac 0.4%

  • Active comparator
    2

    Mineral Oil Emollient

    Drug: Lubricating Eye Drop

Interventions

  • One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days

    Also known as: Acular LS™

  • One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation

    Also known as: Soothe® XP

06

What researchers measure

Primary outcomes

  1. Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels

    The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).

    Time frame: Day 3

07

Results

Posted Sep 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneKetorolac 0.4%Soothe® XP
Started63
Completed63
Not completed00

Outcome measures

PrimaryMean Prostaglandin E2 (PGE2) Aqueous Humor Levels

The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).

Time frame:
Day 3
Reported as:
Mean · Picograms per milliliter (pg/ml)
Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels
Picograms per milliliter (pg/ml)Ketorolac 0.4%Soothe® XP
Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels1027.4 ± 4291014.7 ± 196.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketorolac 0.4%—0/6 (0%)0/6 (0%)
Soothe® XP—0/3 (0%)0/3 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Ketorolac 0.4%Soothe® XPTotal
Mean30.2 ± 9.733.3 ± 2.531.75 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Ketorolac 0.4%Soothe® XPTotal
Female516
Male123
08

Study locations

1 site
  • Houston, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2008
First posted
Nov 14, 2008
Start
Nov 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 23, 2011
Last update
Sep 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00791323
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Nov 14, 2008
Start date
Nov 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 23, 2011
Last update
Sep 23, 2011

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketorolac · Lubricant Eye Drops

Start the discussion